FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2775805903> ?p ?o ?g. }

• W2775805903 endingPage "111" @default.
• W2775805903 startingPage "91" @default.
• W2775805903 abstract "No AccessNov 2017Effectiveness and Cost-Effectiveness of Treatment as Prevention for HIVAuthors/Editors: Charles B. Holmes, Timothy B. Hallett, Rochelle P. Walensky, Till Bärnighausen, Yogan Pillay, Myron S. CohenCharles B. HolmesSearch for more papers by this author, Timothy B. HallettSearch for more papers by this author, Rochelle P. WalenskySearch for more papers by this author, Till BärnighausenSearch for more papers by this author, Yogan PillaySearch for more papers by this author, Myron S. CohenSearch for more papers by this authorhttps://doi.org/10.1596/978-1-4648-0524-0_ch5AboutView ChaptersFull TextPDF (0.2 MB) ToolsAdd to favoritesDownload CitationsTrack Citations ShareFacebookTwitterLinked In Abstract: Establishes the beneficial effects of antiretroviral therapy (ART) as treatment for HIV focusing on four lines of evidence: (1) observational studies of serodiscordant couples, (2) HPTN 052 randomized controlled trial, (3) ecological studies, and (4) population-based studies. Given the effectiveness of treatment for reducing the sexual transmission of HIV, it is increasingly important for policy makers to consider the cost-effectiveness of interventions. Modeling cost-effectiveness also requires examining initiation of treatment earlier in the course of disease than has occurred in most LMICs. Policymakers need to consider questions of trade-offs of expanding testing vs, expanding earlier treatment and what approaches could improve the cost-effectiveness of treatment as prevention. Ongoing research is evaluating the biological, pharmacologic, clinical, and public health elements of ART as a prevention modality. ReferencesAAAS (American Association for the Advancement of Science). 2016. “Entering the Health-Care System: The Challenge of the Universal Test-and-Treat Strategy.” Press release, Eurekalert, July 20. http://www.eurekalert.org/pub_releases/2016-07/a-eth071916.php#.V5TTdKRGkxo.email. Google ScholarAlistar, S S, P M Grant, and E Bendavid 2014. “Comparative Effectiveness and Cost-Effectiveness of Antiretroviral Therapy and Pre-Exposure Prophylaxis for HIV Prevention in South Africa.” BMC Medicine 12 (46): 11. Google ScholarAnderson, B L and S C Cu-Uvin. 2011. “Clinical Parameters Essential to Methodology and Interpretation of Mucosal Responses.” American Journal of Reproductive Immunology 65 (3): 352–60. CrossrefGoogle ScholarAttia, S, M Egger, M Müller, M Zwahlen, and N Low 2009. “Sexual Transmission of HIV According to Viral Load and Antiretroviral Therapy: Systematic Review and Meta-Analysis.” AIDS 23 (11): 1397–404. CrossrefGoogle ScholarBaeten, J M, E Kahle, J R Lingappa, R W Coombs, and S Delany-Moretlwe others. 2011. “Genital HIV-1 RNA Quantity Predicts Risk of Heterosexual HIV-1 Transmission.” Science Translational Medicine 3 (77): 77ra29. CrossrefGoogle ScholarBaggaley, R F, D Dimitrov, B N Owen, M Pickles, and A R Butler others. 2013. “Heterosexual Anal Intercourse: A Neglected Risk Factor for HIV?” American Journal of Reproductive Immunology 69 (1): 95–105. CrossrefGoogle ScholarBaggaley, R F, R G White, T D Hollingsworth, and M C Boily 2013. “Heterosexual HIV-1 Infectiousness and Antiretroviral Use: Systematic Review of Prospective Studies of Discordant Couples.” Epidemiology 24 (1): 110–21. CrossrefGoogle ScholarBärnighausen, T, D E Bloom, and S Humair 2012. “Economics of Antiretroviral Treatment vs. Circumcision for HIV Prevention.” Proceedings of the National Academy of Sciences of the United States of America 109 (52): 21271–76. CrossrefGoogle ScholarBärnighausen, T, J. A Salomon, and N Sangrujee 2012. “HIV Treatment as Prevention: Issues in Economic Evaluation.” PLoS Medicine 9 (7): e1001263. CrossrefGoogle ScholarBoily, M C, B Mâsse, R Alsallaq, N S Padian, and N S Eaton others. 2012. “HIV Treatment as Prevention: Considerations in the Design, Conduct, and Analysis of Cluster Randomized Controlled Trials of Combination HIV Prevention.” PLoS Medicine 9 (7): e1001250. CrossrefGoogle ScholarBoily, M C and Z Shubber 2014. “Modelling in Concentrated Epidemics: Informing Epidemic Trajectories and Assessing Prevention Approaches.” Current Opinion in HIV and AIDS 9 (2): 134–49. CrossrefGoogle ScholarBor, J, A J Herbst, M L Newell, and T Bärnighausen. 2013. “Increases in Adult Life Expectancy in Rural South Africa: Valuing the Scale-Up of HIV Treatment.” Science 339 (6122): 961–65. CrossrefGoogle ScholarBor, J, F Tanser, M L Newell, and T Bärnighausen. 2012. “Nearly Full Employment Recovery among South African HIV Patients on Antiretroviral Therapy: Evidence from a Large Population Cohort.” Health Affairs 31 (7): 10.1377/hlthaff.2012.0407. CrossrefGoogle ScholarBorrow, P 2011. “Innate Immunity in Acute HIV-1 Infection.” Current Opinion in HIV and AIDS 6 (5): 353–63. CrossrefGoogle ScholarBrenner, B, M A Wainberg, and M Roger 2013. “Phylogenetic Inferences on HIV-1 Transmission: Implications for the Design of Prevention and Treatment Interventions.” AIDS 27 (7): 1045–57. CrossrefGoogle ScholarBurns, D N, V DeGruttola, C D Pilcher, M Kretzschmar, and C M Gordon others. 2014. “Toward an Endgame: Finding and Engaging People Unaware of Their HIV-1 Infection in Treatment and Prevention.” AIDS Research and Human Retroviruses 30 (3): 217–24. CrossrefGoogle ScholarCarlson, J M, M Schaefer, D C Monaco, R Batorsky, and D T Claiborne others. 2014. “HIV Transmission: Selection Bias at the Heterosexual HIV-1 Transmission Bottleneck.” Science 345 (6193): 1254031. CrossrefGoogle ScholarCastel, A D, M Befus, S Willis, A Griffin, and S Hader others. 2012. “Use of the Community Viral Load as a Population-Based Biomarker of HIV Burden.” AIDS 26 (3): 345–53. CrossrefGoogle ScholarCDC (Centers for Disease Control and Prevention). 2013. “Botswana Combination Prevention Project (BCPP).” Atlanta, GA. https://clinicaltrials.gov/ct2/show/NCT01965470. Google ScholarChamie, G, D Kwarisiima, T D Clark, J Kabami, and V Jain others. 2012. “Leveraging Rapid Community-Based HIV Testing Campaigns for Non-Communicable Diseases in Rural Uganda.” PLoS One 7 (8): e43400. CrossrefGoogle ScholarCherutich, P, A A Kim, T A Kellogg, K Sherr, and A Waruru others. 2016. “Detectable HIV Viral Load in Kenya: Data from a Population-Based Survey.” PLoS One 11 (5): e0154318. CrossrefGoogle ScholarCohen, M S, Y Chen, M McCauley, T Gamble, and M Hosseinpour 2015. “Final Results of the HPTN 052 Randomized Controlled Trial: Antiretroviral Therapy Prevents HIV Transmission.” International AIDS Society 2015, 8th Conference on HIV Pathogenesis, Treatment, and Prevention, Vancouver, British Columbia, July 19–22. Google ScholarCohen, M S, Y Q Chen, M McCauley, T Gamble, and M C Hosseinipour others. 2011. “Prevention of HIV-1 Infection with Early Antiretroviral Therapy.” New England Journal of Medicine 365 (6): 493–505. CrossrefGoogle ScholarCohen, M S, Y Q Chen, M McCauley, T Gamble, and M C Hosseinipour others. 2016. “Antiretroviral Therapy for the Prevention of HIV-1 Transmission.” New England Journal of Medicine 375: 830–39. CrossrefGoogle ScholarCohen, M S, C Dye, C Fraser, W C Miller, and K A Power others. 2012. “HIV Treatment as Prevention: Debate and Commentary; Will Early Infection Compromise Treatment-as-Prevention Strategies?” PLoS Medicine 9 (7): e1001232. CrossrefGoogle ScholarCohen, M S, C L Gay, M P Busch, and F M Hecht 2010. “The Detection of Acute HIV Infection.” Journal of Infectious Diseases 202 (Suppl 2): S270–77. CrossrefGoogle ScholarCohen, M S, C Holmes, N Padian, M Wolf, and G Himschall others. 2012. “HIV Treatment as Prevention: How Scientific Discovery Occurred and Translated Rapidly into Policy for the Global Response.” Health Affairs 31 (7): 1439–49. CrossrefGoogle ScholarCohen, M S, M K Smith, K E Muessig, T B Hallett, and K A Powers others. 2013. “Antiretroviral Treatment of HIV-1 Prevents Transmission of HIV-1: Where Do We Go from Here?” The Lancet 383 (9903): 1515–24. CrossrefGoogle ScholarCommission on Macroeconomics and Health. 2001. Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization. Google ScholarCope, A B, A M Crooks, T Chin, J D Kuruc, and K S McGee others. 2014. “Incident Sexually Transmitted Infection as a Biomarker for High-Risk Sexual Behavior Following Diagnosis with Acute HIV.” Sexually Transmitted Diseases 41 (7): 447–52. CrossrefGoogle ScholarCu-Uvin, S, A K DeLong, K K Venkatesh, J W Hogan, and J Ingersoll others. 2010. “Genital Tract HIV-1 RNA Shedding among Women with Below Detectable Plasma Viral Load.” AIDS 24 (16): 2489–97. CrossrefGoogle ScholarDanel, C, R Moh, D Gabillard, A Badje, and J Le Carrou others. 2015. “A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.” New England Journal of Medicine 373 (9): 808–22. CrossrefGoogle ScholarDas, M, P L Chu, G M Santos, S Scheer, and E Vittinghoff others. 2010. “Decreases in Community Viral Load Are Accompanied by Reductions in New HIV Infections in San Francisco.” PLoS One 5 (6): e11068. http://dx.doi.org/10.1371/journal.pone.0011068. CrossrefGoogle ScholarDecroo, T, B Telfer, M Biot, J Maikere, and S Dezembro others. 2011. “Distribution of Antiretroviral Treatment through Self-Forming Groups of Patients in Tete Province, Mozambique.” Journal of Acquired Immune Deficiency Syndromes 56 (2): e39–44. CrossrefGoogle ScholarDelva, W, D P Wilson, L Abu-Raddad, M Gorgens, and D Wilson others. 2012. “HIV Treatment as Prevention: Principles of Good HIV Epidemiology Modelling for Public Health Decision-Making in All Modes of Prevention and Evaluation.” PLoS Medicine 9 (7): e1001239. CrossrefGoogle ScholarDHHS (Department of Health and Human Services). 2014. “Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.” Panel on Antiretroviral Guidelines for Adults and Adolescents, DHHS, Washington, DC. Google ScholarDonnell, D, J M Baeten, J Kiarie, K Thomas, and W Stevens others. 2010. “Heterosexual HIV-1 Transmission after Initiation of Antiretroviral Therapy: A Prospective Cohort Analysis.” The Lancet 375 (9731): 2092–98. CrossrefGoogle ScholarDukers, N H, J Goudsmit, J B de Wit, M Prins, and G J Weverling others. 2001. “Sexual Risk Behaviour Relates to the Virological and Immunological Improvements during Highly Active Antiretroviral Therapy in HIV-1 Infection.” AIDS 15 (3): 369–78. CrossrefGoogle ScholarDuncombe, C, S Rosenblum, N Hellman, C Holmes, and L Wilkinson others. 2015. “Reframing HIV Care: Putting People at the Centre of Antiretroviral Delivery.” Tropical Medicine and International Health 20 (4): 430–47. CrossrefGoogle ScholarEaton, J W and T B Hallett 2014. “Why the Proportion of Transmission during Early-Stage HIV Infection Does Not Predict the Long-Term Impact of Treatment on HIV Incidence.” Proceedings of the National Academy of Sciences of the United States of America 111 (45): 16202–7. CrossrefGoogle ScholarEaton, J W, L F Johnson, J A Salomon, T Bärnighausen, and E Bendavid others. 2012. “HIV Treatment as Prevention: Systematic Comparison of Mathematical Models of the Potential Impact of Antiretroviral Therapy on HIV Incidence in South Africa.” PLoS Medicine 9 (7): e1001245. CrossrefGoogle ScholarEaton, J W, N A Menzies, J Stover, V Cambiano, and L Chindelevitch others. 2014. “Health Benefits, Costs, and Cost-Effectiveness of Earlier Eligibility for Adult Antiretroviral Therapy and Expanded Treatment Coverage: A Combined Analysis of 12 Mathematical Models.” The Lancet Global Health 2 (1): e23–34. doi:10.1016/S2214-109X(13)70172-4. CrossrefGoogle ScholarEl Sadr, W, M S Cohen, K DeCock, L G Bekker, and S Karim others. 2011. PEPFAR Scientific Advisory Board Recommendations for the Office of the U.S. Global AIDS Coordinator: Implications of HPTN 052 for PEPFAR’s Treatment Programs. Washington, DC: PEPFAR. https://www.pepfar.gov/documents/organization/177126.pdf. Google ScholarEuropean AIDS Clinical Society. 2014. Guidelines, version 7.1. Copenhagen: European AIDS Clinical Society. http://www.eacsociety.org/files/guidelines_english_71_141204.pdf. Google ScholarFang, C T, H M Hsu, S J Twu, M Y Chen, and Y Y Chang others. 2004. “Decreased HIV Transmission after a Policy of Providing Free Access to Highly Active Antiretroviral Therapy in Taiwan.” Journal of Infectious Diseases 190 (5): 879–85. CrossrefGoogle ScholarGardner, E M, M P McLees, J F Steiner, C Del Rio, and W J Burman 2011. “The Spectrum of Engagement in HIV Care and Its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection.” Clinical Infectious Diseases 52 (6): 793–800. CrossrefGoogle ScholarGarnett, G, S Krishnaratne, K Harris, T Hallet, and M Santos others. 2017. “Cost-Effectiveness of Interventions to Prevent HIV Acquisition.” In Disease Control Priorities (third edition): Volume 6, Major Infectious Diseases, edited by Holmes, K K, S Bertozzi, B R Bloom, and P Jha Washington, DC: World Bank. LinkGoogle ScholarGold, M R, J E Siegel, L B Russell, and M C Weinstein 1996. Cost-Effectiveness in Health and Medicine: Report of the Panel on Cost-Effectiveness in Health and Medicine. New York: Oxford University Press. Google ScholarGoosby, E, D Von Zinkernagel, C B Holmes, D Haroz, and T Walsh 2012. “Raising the Bar: PEPFAR and New Paradigms for Global Health.” Journal of Acquired Immune Deficiency Syndromes 60 (Suppl 3): S158–62. CrossrefGoogle ScholarGranich, R M, C F Gilks, C Dye, K M De Cock, and B G Williams 2009. “Universal Voluntary HIV Testing with Immediate Antiretroviral Therapy as a Strategy for Elimination of HIV Transmission: A Mathematical Model.” The Lancet 373 (9657): 48–57. CrossrefGoogle ScholarGranich, R M, S Gupta, A B Suthar, C Smyth, and D Hoos others. 2011. “Antiretroviral Therapy in Prevention of HIV and TB: Update on Current Research Efforts.” Current HIV Research 9 (6): 446–69. CrossrefGoogle ScholarGranich, R M, J G Kahn, R Bennett, C B Holmes, and N Garg others. 2012. “Expanding ART for Treatment and Prevention of HIV in South Africa: Estimated Cost and Cost-Effectiveness 2011–2050.” PLoS One 7 (2): e30216. CrossrefGoogle ScholarGrinsztejn, B, M C Hosseinipour, H J Ribaudo, S Swindells, and J Eron others. 2014. “Effects of Early Versus Delayed Initiation of Antiretroviral Treatment on Clinical Outcomes of HIV-1 Infection: Results from the Phase 3 HPTN 052 Randomised Controlled Trial.” The Lancet Infectious Diseases 14 (4): 281–90. CrossrefGoogle ScholarHallett, T B, J. W Eaton, and N Menzies 2014. “Beware of Using Invalid Transmission Models to Guide HIV Health Policy: Authors’ Reply.” The Lancet Global Health 2: e261. CrossrefGoogle ScholarHarrispersaud, K, M McNairy, S Ahmed, E J Abrams, and H Thirumurthy others. 2017. “HIV Care Continuum in Adults and Children: Cost-Effectiveness Considerations.” In Disease Control Priorities (third edition): Volume 6, Major Infectious Diseases, edited by Holmes, K K, S Bertozzi, B R Bloom, and P Jha Washington, DC: World Bank. Google ScholarHayes, R, H Ayles, N Beyers, K Sabapathy, and S Floyd others. 2014. “HPTN 071 (PopART): Rationale and Design of a Cluster-Randomised Trial of the Population Impact of an HIV Combination Prevention Intervention Including Universal Testing and Treatment: A Study Protocol for a Cluster Randomised Trial.” Trials 15 (1): 57. CrossrefGoogle ScholarHendrix, C W, E J Fuchs, K J Macura, L A Lee, and T L Parsons others. 2008. “Quantitative Imaging and Sigmoidoscopy to Assess Distribution of Rectal Microbicide Surrogates.” Clinical Pharmacology and Therapeutics 83 (1): 97–105. CrossrefGoogle ScholarHenry, K 1988. “Setting AIDS Priorities: The Need for a Closer Alliance of Public Health and Clinical Approaches toward the Control of AIDS.” American Journal of Public Health 78 (9): 1210–12. CrossrefGoogle ScholarHo, Y C, L Shan, N N Hosmane, J Wang, and S B Laskey others. 2013. “Replication-Competent Non-Induced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure.” Cell 155 (3): 540–51. CrossrefGoogle ScholarHollingsworth, T D, R. M Anderson, and C Fraser 2008. “HIV-1 Transmission, by Stage of Infection.” Journal of Infectious Diseases 198 (5): 687–93. CrossrefGoogle ScholarHolmes, C B, J M Blandford, N Sangrujee, S R Stewart, and A Dubois others. 2012. “PEPFAR’s Past and Future Efforts to Cut Costs, Improve Efficiency, and Increase the Impact of Global HIV Programs.” Health Affairs 31 (7): 1553–60. CrossrefGoogle ScholarHolmes, C B, W Coggin, D Jamieson, H Mihm, and R Granich others. 2010. “Use of Generic Antiretroviral Agents and Cost Savings in PEPFAR Treatment Programs.” Journal of the American Medical Association 304 (3): 313–20. CrossrefGoogle ScholarHolmes, C B and I Sanne 2015. “Changing Models of Care to Improve Progression through the HIV Treatment Cascade in Different Populations.” Current Opinion in HIV and AIDS 10 (6): 447–50. CrossrefGoogle ScholarHolmes, C B, R Wood, M Badri, S Zilber, and B Wang others. 2006. “CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa: Implications for Prophylaxis and Treatment.” Journal of Acquired Immune Deficiency Syndromes 42 (4): 464–69. CrossrefGoogle ScholarHontelez, J A, A Y Chang, O Ogbuoji, S J Vlas, and T Bärnighausen others. 2016. “Changing HIV Treatment Eligibility under Health System Constraints in Sub-Saharan Africa: Investment Needs, Population Health Gains, and Cost-Effectiveness.” AIDS 30 (150): 2341–50. CrossrefGoogle ScholarHontelez, J A C, S J de Vlas, F Tanser, R Bakker, and T Bärnighausen others. 2011. “The Impact of the New WHO Antiretroviral Treatment Guidelines on HIV Epidemic Dynamics and Cost in South Africa.” PLoS One 6 (7): e21919. CrossrefGoogle ScholarINSIGHT START Study Group. 2015. “Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.” New England Journal of Medicine 373 (9): 795–807. CrossrefGoogle ScholarIwuji, C C, J Orne-Gliemann, E Balestre, J Larmarange, and R Thiebaut others. 2016. “The Impact of Universal Test and Treat on HIV Incidence in a Rural South African Population: ANRS 12249 TasP Trial, 2012–2016.” 21st International AIDS Conference (AIDS 2016), Durban, South Africa, July 18–22. Google ScholarIwuji, C, J Orne-Gliemann, J Larmarange, N Okesola, and F Tanser others. 2016. “Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural Kwazulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised Trial.” PLoS Medicine 13 (8): e1002107. CrossrefGoogle ScholarIwuji, C C, J Orne-Gliemann, F Tanser, S Boyer, and R J Lessells others. 2013. “Evaluation of the Impact of Immediate Versus WHO Recommendations: Guided Antiretroviral Therapy Initiation on HIV Incidence; the ANRS 12249 TasP (Treatment as Prevention) Trial in Hlabisa Sub-district, KwaZulu-Natal, South Africa, Study Protocol for a Cluster Randomized Control Trial.” Trials 14 (1): 230. Google ScholarJain, V, T Liegler, J Kabami, G Chamie, and T D Clark others. 2013. “Assessment of Community Viral Load in a Rural East African Setting Using a Fingerprick-Based Blood Collection Method.” Clinical Infectious Diseases 56 (4): 598–605. CrossrefGoogle ScholarJanssen, R S, G A Satten, S L Stramer, B D Rawal, and T R O’Brien others. 1998. “New Testing Strategy to Detect Early HIV-1 Infection for Use in Incidence Estimates and for Clinical and Prevention Purposes.” Journal of the American Medical Association 280 (1): 42–48. CrossrefGoogle ScholarJia, Z, Y Mao, F Zhang, Y Ruan, and Y Ma others. 2012. “Antiretroviral Therapy to Prevent HIV Transmission in Serodiscordant Couples in China (2003–11): A National Observational Cohort Study.” The Lancet 382 (9899): 1195–203. CrossrefGoogle ScholarJohn-Stewart, G, R Peeling, C Levin, P J Garcia, and D Mabey others. 2017. “Elimination of Mother-to-Child Transmission of HIV and Syphilis.” In Disease Control Priorities (third edition): Volume 6, Major Infectious Diseases, edited by Holmes, K K, S Bertozzi, B R Bloom, and P Jha Washington, DC: World Bank. Google ScholarJoseph, S B, K T Arrildt, A E Swanstrom, G Schnell, and B Lee others. 2014. “Quantification of Entry Phenotypes of Macrophage-Tropic HIV-1 across a Wide Range of CD4 Densities.” Journal of Virology 88 (4): 1858–69. CrossrefGoogle ScholarKaiser Family Foundation. 2015. “Financing the Response to HIV in Low- and Middle-Income Countries: International Assistance from Donor Governments in 2015.” Kaiser Family Foundation, Menlo Park, CA. http://files.kff.org/attachment/Financing-the-Response-to-HIV-in-Low-and-Middle-Income-Countries-International-Assistance-from-Donor-Governments-in-2015. Google ScholarKalichman, S C, C Cherry, C M Amaral, C Swetzes, and L Eaton others. 2010. “Adherence to Antiretroviral Therapy and HIV Transmission Risks: Implications for Test-and-Treat Approaches to HIV Prevention.” AIDS Patient Care and STDs 24 (5): 271–77. CrossrefGoogle ScholarKatz, M H, S K Schwarcz, T A Kellogg, J D Klausner, and J W Dilley others. 2002. “Impact of Highly Active Antiretroviral Treatment on HIV Seroincidence among Men Who Have Sex with Men: San Francisco.” American Journal of Public Health 92 (3): 388–94. CrossrefGoogle ScholarKeele, B F, E E Giorgi, J F Salazar-Gonzalez, J M Decker, and K T Pham others. 2008. “Identification and Characterization of Transmitted and Early Founder Virus Envelopes in Primary HIV-1 Infection.” Proceedings of the National Academy of Sciences of the United States of America 105 (21): 7552–57. CrossrefGoogle ScholarKitahata, M M, S J Gange, A G Abraham, B Merriman, and M S Saaq others. 2009. “Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival.” New England Journal of Medicine 360 (18): 1815–26. CrossrefGoogle ScholarKwara, A, A Delong, N Rezk, J Hogan, and H Burtwell others. 2008. “Antiretroviral Drug Concentrations and HIV RNA in the Genital Tract of HIV-Infected Women Receiving Long-Term Highly Active Antiretroviral Therapy.” Clinical Infectious Diseases 46 (5): 719–25. CrossrefGoogle ScholarLaeyendecker, O, R Brookmeyer, C E Mullis, D Donnell, and J Lingappa others. 2012. “Specificity of Four Laboratory Approaches for Cross-Sectional HIV Incidence Determination: Analysis of Samples from Adults with Known Nonrecent HIV Infection from Five African Countries.” AIDS Research and Human Retroviruses 28 (10): 1177–83. CrossrefGoogle ScholarLaw, M G, I Woolley, D J Templeton, N Roth, and J Chuah others. 2011. “Trends in Detectable Viral Load by Calendar Year in the Australian HIV Observational Database.” Journal of the International AIDS Society 14 (1): 10. CrossrefGoogle ScholarLe Vu, S, J Pillonel, C Semaille, P Bernillon, and Y Le Strat others. 2008. “Principles and Uses of HIV Incidence Estimation from Recent Infection Testing: A Review.” Eurosurveillance 13 (36): 11–16. Google ScholarLi, H, K J Bar, S Wang, J M Decker, and Y Chen others. 2010. “High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men.” PLoS Pathogens 6 (5): e1000890. CrossrefGoogle ScholarLima, V D, K Johnston, R S Hogg, A R Levy, and P R Harrigan others. 2008. “Expanded Access to Highly Active Antiretroviral Therapy: A Potentially Powerful Strategy to Curb the Growth of the HIV Epidemic.” Journal of Infectious Diseases 198 (1): 59–67. CrossrefGoogle ScholarLinas, B P, H Zheng, E Losina, A Rockwell, and R P Walensky others. 2006. “Optimizing Resource Allocation in United States AIDS Drug Assistance Programs.” Clinical Infectious Diseases 43 (10): 1357–64. CrossrefGoogle ScholarLong, E F, M. L Brandeau, and D K Owens 2010. “The Cost-Effectiveness and Population Outcomes of Expanded HIV Screening and Antiretroviral Treatment in the United States.” Annals of Internal Medicine 153 (12): 778–89. CrossrefGoogle ScholarLopez-Quintero, C, R Shtarkshall, and Y D Neumark 2005. “Barriers to HIV-Testing among Hispanics in the United States: Analysis of the National Health Interview Survey.” AIDS Patient Care and STDs 19 (10): 672–83. CrossrefGoogle ScholarLoutfy, M R, W Wu, M Letchumanan, L Bondy, and T Antoniou others. 2013. “Systematic Review of HIV Transmission between Heterosexual Serodiscordant Couples Where the HIV-Positive Partner Is Fully Suppressed on Antiretroviral Therapy.” PLoS One 8 (2): e55747. CrossrefGoogle ScholarLu, W, G Zeng, J Luo, S Duo, and G Xing others. 2010. “HIV Transmission Risk among Serodiscordant Couples: A Retrospective Study of Former Plasma Donors in Henan, China.” Journal of Acquired Immune Deficiency Syndromes 55 (2): 2332–38 Google ScholarMaddali, M V, D W Dowdy, A Gupta, and M Shah 2015. “Economic and Epidemiological Impact of Early Antiretroviral Therapy Initiation in India.” Journal of the International AIDS Society 18: 20217. CrossrefGoogle ScholarMargolis, D, C Brinson, J Eron, G Richmond, and R LeBlanc others. 2014. “744 and Rilpivirine as Two-Drug Oral Maintenance Therapy: LAI116482 (LATTE) Week 48 Results.” Special Issue: Abstracts from the 2014 Conference on Retroviruses and Opportunistic Infections. Topics in Antiviral Medicine International 22 (e-1): 34. Google ScholarMartin, E, J M Carlson, A Q Le, D R Chopera, and R McGovern others. 2014. “Early Immune Adaptation in HIV-1 Revealed by Population-Level Approaches.” Retrovirology 11 (64): 1–16. Google ScholarMcLaren, P J, C Coulonges, S Ripke, L van den, and S Buchbinder Berg others. 2013. “Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls.” PLoS Pathogens 9 (7): e1003515. CrossrefGoogle ScholarMeyer-Rath, G and M Over 2012. “HIV Treatment as Prevention: Modelling the Cost of Antiretroviral Treatment—State of the Art and Future Directions.” PLoS Medicine 9 (7): e1001247. CrossrefGoogle ScholarMontaner, J S, E Wood, T Kerr, V Lima, and R Barrios others. 2010. “Expanded Highly Active Antiretroviral Therapy Coverage among HIV-Positive Drug Users to Improve Individual and Public Health Outcomes.” Journal of Acquired Immune Deficiency Syndromes 55 (1): S5–S9. CrossrefGoogle ScholarMuessig, K E and M S Cohen 2014. “Advances in HIV Prevention for Serodiscordant Couples.” Current HIV/AIDS Reports 11 (4): 434–46. CrossrefGoogle ScholarNachega, J B, O A Uthman, E J Mills, and T C Quinn 2013. “Adherence to Antiretroviral Therapy for the Success of Emerging Interventions to Prevent HIV Transmission: A Wake-Up Call.” Journal of AIDS and Clinical Research (Suppl 4):2039–52. Google ScholarNational AIDS and STI Control Programme. 2013. “Kenya AIDS Indicator Survey 2012.” Ministry of Health, Nairobi, Kenya. Google ScholarNichols, B E, R Baltussen, J H van Dijk, P Thuma, and J L Nouwen others. 2014. “Cost-Effectiveness of PrEP in HIV/AIDS Control in Zambia: A Stochastic League Approach.” Journal of Acquired Immune Deficiency Syndromes 66 (2): 221–28. CrossrefGoogle ScholarNovitsky, V, R Wang, S Lagakos, and M Essex 2010. “HIV-1 Subtype C Phylodynamics in the Global Epidemic.” Viruses 2 (1): 33–54. CrossrefGoogle ScholarO’Brien, T R, D H McDermott, J P Ionnidis, M Carrington, and P M Murphy others. 2000. “Effect of Chemokine Receptor Gene Polymorphisms on the Response to Potent Antiretroviral Therapy.” AIDS 14 (7): 821–26. CrossrefGoogle ScholarOkano, J T and S Blower 2014. “Beware of Using Invalid Transmission Models to Guide HIV Health Policy.” The Lancet Global Health 2 (5): e260. CrossrefGoogle ScholarOlivier, A J, L Masson, K Ronacher, G Walzl, and D Coetzee others. 2014. “Distinct Cytokine Patterns in Semen Influence Local HIV Shedding and HIV Target Cell Panel Activation.” Journal of Infectious Diseases 209 (8): 1174–84. CrossrefGoogle ScholarPatterson, K B, H A Prince, E Kraft, A J Jenkins, and N J Shaheen others. 2011. “Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission.” Science Translational Medicine 3 (112): 112. CrossrefGoogle ScholarParrish, N F, F Gao, H Li, E E Giorgi, and H J Barbian others. 2013. “Phenotypic Properties of Transmitted Founder HIV-1.” Proceedings of the National Academy of Sciences of the United States of America 110 (17): 6626–33. CrossrefGoogle ScholarPEPFAR (President’s Emergency Plan for AIDS Relief). 2012. “Report on Pilot Expenditure Analysis of PEPFAR Programs in Six Countries.” Department of State, Washington, DC. http://www.pepfar.gov/documents/organization/195700.pdf. Google ScholarPEPFAR (President’s Emergency Plan for AIDS Relief). 2014. PEPFAR 3.0 Controlling the Epidemic: Delivering on the Promise of an AIDS-free Generation. Washington, DC: The Office of the U.S. Global AIDS Coordinator. http://www.pepfar.gov/documents/organization/234744.pdf. Google ScholarPEPFAR (President’s Emergency Plan for AIDS Relief). 2015. “2015 United Nations General Assembly Sustainable Development Summit.” Fact Sheet, Department of State, Washington, DC. http://www.pepfar.gov/documents/organization/247548.pdf. Google ScholarPilcher, C D, J. J Eron Jr, S Galvin, C Gay, and M S Cohen 2004. “Acute HIV Revisited: New Opportunities for Treatment and Prevention.” Journal of Clinical Investigation 113 (7): 937–45. CrossrefGoogle ScholarPilcher, C D, G Joak, I F Hoffman, F E A Martinson, and C Mapanje others. 2007. “Amplified Transmission of HIV-1: Comparison of HIV-1 Concentrations in Semen and Blood during Acute and Chronic Infection.” AIDS 21 (13): 1723–30. CrossrefGoogle ScholarPing, L H, S B Joseph, J A Anderson, M R Abrahams, and J F Salazar-Gonzalez others. 2013. “Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design.” Journal of Virology 87 (13): 7218–33. CrossrefGoogle ScholarPorco, T C, J N Martin, K A Page-Shafer, A Cheng, and E Charlebois others. 2004. “Decline in HIV Infectivity Following the Introduction of Highly Active Antiretroviral Therapy.” AIDS 18 (1): 81–88. CrossrefGoogle ScholarPowers, K A, M" @default.
• W2775805903 created "2017-12-22" @default.
• W2775805903 creator A5003138186 @default.
• W2775805903 creator A5024262342 @default.
• W2775805903 creator A5044322042 @default.
• W2775805903 creator A5060417393 @default.
• W2775805903 creator A5074838021 @default.
• W2775805903 creator A5086465511 @default.
• W2775805903 date "2017-11-06" @default.
• W2775805903 modified "2023-09-25" @default.
• W2775805903 title "Effectiveness and Cost-Effectiveness of Treatment as Prevention for HIV" @default.
• W2775805903 cites W1695936679 @default.
• W2775805903 cites W1926101189 @default.
• W2775805903 cites W1951090602 @default.
• W2775805903 cites W1963704583 @default.
• W2775805903 cites W1964831430 @default.
• W2775805903 cites W1967855332 @default.
• W2775805903 cites W1969274526 @default.
• W2775805903 cites W1973540642 @default.
• W2775805903 cites W1973597065 @default.
• W2775805903 cites W1976226854 @default.
• W2775805903 cites W1976380667 @default.
• W2775805903 cites W1978936752 @default.
• W2775805903 cites W1980305166 @default.
• W2775805903 cites W1981618969 @default.
• W2775805903 cites W1984485461 @default.
• W2775805903 cites W1987792428 @default.
• W2775805903 cites W1988151748 @default.
• W2775805903 cites W1992217226 @default.
• W2775805903 cites W1994040758 @default.
• W2775805903 cites W1997500258 @default.
• W2775805903 cites W1999903925 @default.
• W2775805903 cites W2001592513 @default.
• W2775805903 cites W2002574877 @default.
• W2775805903 cites W2002851422 @default.
• W2775805903 cites W2003864666 @default.
• W2775805903 cites W2007089157 @default.
• W2775805903 cites W2008792371 @default.
• W2775805903 cites W2027716154 @default.
• W2775805903 cites W2027775943 @default.
• W2775805903 cites W2028605145 @default.
• W2775805903 cites W2029558670 @default.
• W2775805903 cites W2036408211 @default.
• W2775805903 cites W2038051569 @default.
• W2775805903 cites W2038942061 @default.
• W2775805903 cites W2039617800 @default.
• W2775805903 cites W2043951092 @default.
• W2775805903 cites W2046584457 @default.
• W2775805903 cites W2047057976 @default.
• W2775805903 cites W2050326976 @default.
• W2775805903 cites W2052191760 @default.
• W2775805903 cites W2055429590 @default.
• W2775805903 cites W2056334242 @default.
• W2775805903 cites W2057912460 @default.
• W2775805903 cites W2063280782 @default.
• W2775805903 cites W2065464437 @default.
• W2775805903 cites W2066646925 @default.
• W2775805903 cites W2069336849 @default.
• W2775805903 cites W2073966181 @default.
• W2775805903 cites W2075453224 @default.
• W2775805903 cites W2077753323 @default.
• W2775805903 cites W2080807877 @default.
• W2775805903 cites W2082509221 @default.
• W2775805903 cites W2096658475 @default.
• W2775805903 cites W2097457247 @default.
• W2775805903 cites W2100430786 @default.
• W2775805903 cites W2101429325 @default.
• W2775805903 cites W2103115327 @default.
• W2775805903 cites W2106626856 @default.
• W2775805903 cites W2108603500 @default.
• W2775805903 cites W2109064013 @default.
• W2775805903 cites W2110579674 @default.
• W2775805903 cites W2112464708 @default.
• W2775805903 cites W2115580899 @default.
• W2775805903 cites W2115880176 @default.
• W2775805903 cites W2116560165 @default.
• W2775805903 cites W2117486600 @default.
• W2775805903 cites W2118351251 @default.
• W2775805903 cites W2119698484 @default.
• W2775805903 cites W2120637537 @default.
• W2775805903 cites W2122293763 @default.
• W2775805903 cites W2124288260 @default.
• W2775805903 cites W2125219944 @default.
• W2775805903 cites W2126401413 @default.
• W2775805903 cites W2127280664 @default.
• W2775805903 cites W2127617134 @default.
• W2775805903 cites W2127832030 @default.
• W2775805903 cites W2128158558 @default.
• W2775805903 cites W2128431602 @default.
• W2775805903 cites W2130416821 @default.
• W2775805903 cites W2131295062 @default.
• W2775805903 cites W2132201801 @default.
• W2775805903 cites W2132439494 @default.
• W2775805903 cites W2134911122 @default.
• W2775805903 cites W2136460596 @default.
• W2775805903 cites W2137160100 @default.
• W2775805903 cites W2137565361 @default.
• W2775805903 cites W2140789060 @default.

• next